1. Home
  2. ZYME vs ASTE Comparison

ZYME vs ASTE Comparison

Compare ZYME & ASTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ZYME
  • ASTE
  • Stock Information
  • Founded
  • ZYME 2003
  • ASTE 1972
  • Country
  • ZYME United States
  • ASTE United States
  • Employees
  • ZYME N/A
  • ASTE N/A
  • Industry
  • ZYME Biotechnology: Pharmaceutical Preparations
  • ASTE Construction/Ag Equipment/Trucks
  • Sector
  • ZYME Health Care
  • ASTE Industrials
  • Exchange
  • ZYME Nasdaq
  • ASTE Nasdaq
  • Market Cap
  • ZYME 968.5M
  • ASTE 915.1M
  • IPO Year
  • ZYME 2017
  • ASTE N/A
  • Fundamental
  • Price
  • ZYME $12.43
  • ASTE $39.38
  • Analyst Decision
  • ZYME Buy
  • ASTE Hold
  • Analyst Count
  • ZYME 7
  • ASTE 1
  • Target Price
  • ZYME $19.50
  • ASTE $41.00
  • AVG Volume (30 Days)
  • ZYME 409.0K
  • ASTE 173.4K
  • Earning Date
  • ZYME 08-07-2025
  • ASTE 08-06-2025
  • Dividend Yield
  • ZYME N/A
  • ASTE 1.33%
  • EPS Growth
  • ZYME N/A
  • ASTE N/A
  • EPS
  • ZYME N/A
  • ASTE 2.01
  • Revenue
  • ZYME $93,384,000.00
  • ASTE $1,310,100,000.00
  • Revenue This Year
  • ZYME $44.71
  • ASTE $5.43
  • Revenue Next Year
  • ZYME $34.57
  • ASTE $4.22
  • P/E Ratio
  • ZYME N/A
  • ASTE $19.50
  • Revenue Growth
  • ZYME 85.05
  • ASTE 1.17
  • 52 Week Low
  • ZYME $9.03
  • ASTE $29.04
  • 52 Week High
  • ZYME $17.70
  • ASTE $43.35
  • Technical
  • Relative Strength Index (RSI)
  • ZYME 40.44
  • ASTE 48.05
  • Support Level
  • ZYME $12.26
  • ASTE $37.88
  • Resistance Level
  • ZYME $13.80
  • ASTE $41.05
  • Average True Range (ATR)
  • ZYME 0.62
  • ASTE 1.40
  • MACD
  • ZYME -0.21
  • ASTE 0.02
  • Stochastic Oscillator
  • ZYME 10.19
  • ASTE 27.23

About ZYME Zymeworks Inc.

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

About ASTE Astec Industries Inc.

Astec Industries Inc designs and manufactures equipment and components used in road construction and other development activities. Its products are used through the entire process of building roads, from mining and crushing materials to creating the road surface. The company manufactures a line of plants, pavers, vehicles, and machines to mix and transform materials into construction components. It has two operating segments: infrastructure solutions generating maximum revenue and materials solutions. The majority of sales are derived from the United States. Its customers are asphalt producers, highway and heavy equipment contractors, ready mix concrete producers, demolition recycling markets, sand and gravel producers, open mine operators, quarry operators, and others.

Share on Social Networks: